Company Overview - Spyre Therapeutics, Inc. is a preclinical-stage biotechnology company focused on developing novel antibody-based therapies for inflammatory bowel disease (IBD) [6][8] - The company has a pipeline that includes monoclonal antibody therapeutics targeting IBD, specifically SPY001 (anti-a4ß7) and SPY002 (anti-TL1A), along with combination therapies [8][9] - Spyre Therapeutics aims to address significant unmet medical needs in gastrointestinal health and is positioned to compete in the evolving IBD therapeutics market [9] Financial Metrics - As of March 18, 2026, Spyre Therapeutics has a market capitalization of $3.38 billion and a share price of $43.03, reflecting a one-year price change of 132.1% [4][7] - The net income for the trailing twelve months (TTM) is reported at a loss of $135.82 million [4] - The estimated value of VR Adviser, LLC's holding in Spyre Therapeutics increased by $75.73 million during the fourth quarter, which includes both share purchases and price appreciation [2][6] Investment Activity - On February 17, 2026, VR Adviser, LLC disclosed the purchase of 1,000,000 shares of Spyre Therapeutics, valued at approximately $25.78 million based on quarterly average pricing [1][2] - This acquisition increased VR Adviser's stake in Spyre Therapeutics to 5.96% of its reportable U.S. equity assets, with a total of 3,685,448 shares valued at $120.74 million as of December 31, 2025 [6][7] - Spyre Therapeutics remains a significant holding within VR Adviser's 27-position U.S. equity portfolio [6]